Repligen replies to the needs of the pharmaceutical industry by supplying bioengineered drug ingredients. Repligen's bioprocessing business develops and commercializes proteins and other agents used in the production of biopharmaceuticals. The firm also conducts drug research activities include development of a pancreatic imaging agent and potential therapies for bipolar disorder, Friedreich's ataxia (a debilitating early adulthood disease), and spinal muscular atrophy. While all of Repligen's own drugs are in the clinical development stage, it does receive royalty payments from Bristol-Myers Squibb (BMS) on sales of BMS' Orencia rheumatoid arthritis drug, as well as by licensing out its technologies.